Breakthrough new medicines for hepatitis C and drug-resistant TB and largest-yet global programme for seasonal malaria chemoprevention to be made available for low- and middle-income countries

Read online at:
http://www.unitaid.org/en/resources/press-centre/releases/1352-unitaid-approves-grants-of-160-millionUTD_logo

The UNITAID Executive Board committed US$ 160 million in new grants, including investments to ensure low- and middle-income populations have access to new high performing treatments for hepatitis C and drug-resistant tuberculosis, and the largest-yet global programme for seasonal malaria chemoprevention. These innovative investments will reduce prices, overcome market barriers to access for patients, and generate crucial data on new products to speed up their introduction for those most in need.

(Visited 31 times, 1 visits today)
This entry was posted in Essential Medicines, General, Other Infectious Diseases. Bookmark the permalink.